CreativeOne Wealth LLC Grows Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

CreativeOne Wealth LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 182.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,446 shares of the company’s stock after purchasing an additional 2,873 shares during the quarter. CreativeOne Wealth LLC’s holdings in Medpace were worth $1,484,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Signaturefd LLC boosted its holdings in shares of Medpace by 4.9% in the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after acquiring an additional 26 shares in the last quarter. Wealth Alliance lifted its position in Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock valued at $399,000 after purchasing an additional 27 shares during the period. Centaurus Financial Inc. boosted its holdings in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after purchasing an additional 29 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in Medpace by 0.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares in the last quarter. Finally, Lindenwold Advisors INC increased its position in Medpace by 1.6% during the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $338.96 on Friday. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77. The stock has a market cap of $10.53 billion, a PE ratio of 29.68, a price-to-earnings-growth ratio of 1.88 and a beta of 1.37. The business’s fifty day moving average price is $338.32 and its two-hundred day moving average price is $371.75.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. The firm had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.22 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MEDP. Truist Financial decreased their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. TD Cowen dropped their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Finally, StockNews.com lowered Medpace from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.